Targeting BCMA in Multiple Myeloma

被引：10

作者：

Tan, Carlyn Rose ^{[1
]}

Shah, Urvi A. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Myeloma Serv Dept Med, 530 E 74th St, New York, NY 10021 USA

来源：

CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2021年 / 16卷 / 05期

关键词：

Multiple myeloma; BCMA; CAR T cell therapy; Bispecific antibody constructs; Antibody-drug conjugates; CELL MATURATION ANTIGEN; BISPECIFIC ANTIBODY; PRECLINICAL ACTIVITY; OPEN-LABEL; T-CELLS; RECEPTOR; GENERATION; EXPRESSION; BORTEZOMIB; SURVIVAL;

D O I：

10.1007/s11899-021-00639-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of Review Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a significant number of patients still progress on current available therapies. Here, we review treatment modalities used to target BCMA in the treatment of MM, specifically antibody-drug conjugates (ADC), bispecific antibody constructs, and chimeric antibody receptor (CAR) modified T-cell therapies. We will provide an overview of therapies from these classes that have presented or published clinical data, as well as data on mechanisms of resistance to these novel agents. Recent Findings Clinical trials exploring different BCMA-targeting modalities to treat multiple myeloma are underway and demonstrate promising results. In relapsed/refractory multiple myeloma, anti-BCMA ADCs and bispecific antibody constructs are showing impressive efficacy with manageable side effect profiles. In parallel, adoptive cellular therapy has induced dramatic durable responses in multiply relapsed and refractory myeloma patients. Therapeutic approaches targeting BCMA hold significant potential in the management of multiple myeloma and will soon be incorporated in combination with current standard therapies to improve outcomes for patients with multiple myeloma. In addition, novel approaches are being evaluated to overcome resistance mechanisms to anti-BCMA therapies.

引用

页码：367 / 383

页数：17

共 79 条

[1] Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes [J].

Alsina, Melissa ;

Shah, Nina ;

Raje, Noopur S. ;

Jagannath, Sundar ;

Madduri, Deepu ;

Kaufman, Jonathan L. ;

Siegel, David S. ;

Munshi, Nikhil C. ;

Rosenblatt, Jacalyn ;

Lin, Yi ;

Jakubowiak, Andrzej ;

Jasielec, Jagoda ;

Timm, Alison ;

Turka, Ashley ;

Mao, Pingping ;

Martin, Nathan ;

Campbell, Timothy B. ;

Hege, Kristen ;

Bitter, Hans ;

Petrocca, Fabio ;

Berdeja, Jesus G. .

BLOOD, 2020, 136

[2] T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma [J].

Brudno, Jennifer N. ;

Maric, Irina ;

Hartman, Steven D. ;

Rose, Jeremy J. ;

Wang, Michael ;

Lam, Norris ;

Stetler-Stevenson, Maryalice ;

Salem, Dalia ;

Yuan, Constance ;

Pavletic, Steven ;

Kanakry, Jennifer A. ;

Ali, Syed Abbas ;

Mikkilineni, Lekha ;

Feldman, Steven A. ;

Stroncek, David F. ;

Hansen, Brenna G. ;

Lawrence, Judith ;

Patel, Rashmika ;

Hakim, Frances ;

Gress, Ronald E. ;

Kochenderfer, James N. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) :2267-+

[3] Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells [J].

Chen, Haiming ;

Li, Mingjie ;

Xu, Ning ;

Ng, Nicole ;

Sanchez, Eric ;

Soof, Camilia M. ;

Patil, Saurabh ;

Udd, Kyle ;

Bujarski, Sean ;

Cao, Jasmin ;

Hekmati, Tara ;

Ghermezi, Matthew ;

Zhou, Mizi ;

Wang, Emily Y. ;

Tanenbaum, Edward J. ;

Zahab, Brian ;

Schlossberg, Remy ;

Yashar, Moryel A. ;

Wang, Cathy S. ;

Tang, George Y. ;

Spektor, Tanya M. ;

Berenson, James R. .

LEUKEMIA RESEARCH, 2019, 81 :62-66

[4] Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies [J].

Cohen, Adam D. ;

Garfall, Alfred L. ;

Dogan, Ahmet ;

Lacey, Simon F. ;

Martin, Chris ;

Lendvai, Nikoletta ;

Vogl, Dan T. ;

Spear, Matthew ;

Lesokhin, Alexander M. .

BLOOD ADVANCES, 2019, 3 (16) :2487-2490

[5] B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma [J].

Cohen, Adam D. ;

Garfall, Alfred L. ;

Stadtmauer, Edward A. ;

Melenhorst, J. Joseph ;

Lacey, Simon F. ;

Lancaster, Eric ;

Vogl, Dan T. ;

Weiss, Brendan M. ;

Dengel, Karen ;

Nelson, Annemarie ;

Plesa, Gabriela ;

Chen, Fang ;

Davis, Megan M. ;

Hwang, Wei-Ting ;

Young, Regina M. ;

Brogdon, Jennifer L. ;

Isaacs, Randi ;

Pruteanu-Malinici, Iulian ;

Siegel, Don L. ;

Levine, Bruce L. ;

June, Carl H. ;

Milone, Michael C. .

JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (06) :2210-2221

[6] First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial [J].

Costa, Luciano J. ;

Wong, Sandy W. ;

Bermudez, Arancha ;

de la Rubia, Javier ;

Mateos, Maria-Victoria ;

Ocio, Enrique M. ;

Rodriguez-Otero, Paula ;

San-Miguel, Jesus ;

Li, Shaoyi ;

Sarmiento, Rafael ;

Lardelli, Pilar ;

Gaudy, Allison ;

Boss, Isaac ;

Kelly, Lisa M. ;

Burgess, Michael R. ;

Hege, Kristen ;

Bensinger, William I. .

BLOOD, 2019, 134

[7] Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies [J].

Costello, Caitlin L. ;

Cohen, Adam D. ;

Patel, Krina K. ;

Ali, Syed S. ;

Berdeja, Jesus G. ;

Shah, Nina ;

Ganguly, Siddhartha ;

Kocoglu, Mehmet Hakan ;

Abedi, Mehrdad ;

Ostertag, Eric M. ;

Martin, Chris E. ;

Ghoddussi, Majid ;

Shedlock, Devon J. ;

McCaigue, Joanne ;

Namini, Hamid ;

Yalamanchili, Sreeni ;

Spear, Matthew A. ;

Gregory, Tara K. .

BLOOD, 2020, 136

[8] Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma [J].

Cowan, Andrew J. ;

Pont, Margot ;

Sather, Blythe Duke ;

Turtle, Cameron J. ;

Till, Brian G. ;

Nagengast, Anne M. ;

Libby, Edward N., III ;

Becker, Pamela S. ;

Coffey, David G. ;

Tuazon, Sherilyn A. ;

Wood, Brent L. ;

Blake, Michelle L. ;

Works, Melissa G. ;

Gooley, Ted A. ;

Wu, Qian Vicky ;

Maloney, David G. ;

Riddell, Stanley R. ;

Green, Damian J. .

BLOOD, 2019, 134

[9] Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma [J].

de Larrea, Carlos Fernandez ;

Staehr, Mette ;

Lopez, Andrea, V ;

Ng, Khong Y. ;

Chen, Yunxin ;

Godfrey, William D. ;

Purdon, Terence J. ;

Ponomarev, Vladimir ;

Wendel, Hans-Guido ;

Brentjens, Renier J. ;

Smith, Eric L. .

BLOOD CANCER DISCOVERY, 2020, 1 (02) :146-154

[10] Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial [J].

Durie, Brian G. M. ;

Hoering, Antje ;

Abidi, Muneer H. ;

Rajkumar, S. Vincent ;

Epstein, Joshua ;

Kahanic, Stephen P. ;

Thakuri, Mohan ;

Reu, Frederic ;

Reynolds, Christopher M. ;

Sexton, Rachael ;

Orlowski, Robert Z. ;

Barlogie, Bart ;

Dispenzieri, Angela .

LANCET, 2017, 389 (10068) :519-527

← 1 2 3 4 5 6 7 8 →